Cheplapharm Arzneimittel GmbH

acquired/legacy branded pharmaceuticals (specialty licensing and commercialization)

Privately held: no public share price · Germany

Assets

(11 total)
11Total Assets
11Approved
0Phase 3 / Filed
0Phase 1–2 / Early
13Diseases
Quick filter:
Showing 11 of 11 assets
Target & Modality
Approved
Glucocorticoid receptor agonistSmall molecule
Asthma
Approved
Fluoropyrimidine (antimetabolite)Small molecule
Breast CancerColorectal CancerGastric CancerPancreatic Cancer
HR+/HER2- Metastatic Breast Cancer, Metastatic Colorectal Cancer
Approved
EGFRSmall molecule
Non-Small Cell Lung CancerPancreatic Cancer
Approved
Ribonucleotide reductaseSmall molecule
Sickle Cell Disease
Approved
Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule
Schizophrenia
Approved
Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule
SchizophreniaBipolar Disorder
orlistat(Xenical)
Approved
Pancreatic/gastric lipaseSmall molecule
Obesity
Approved
Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule
Major Depressive DisorderSchizophreniaBipolar Disorder
Approved
Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule
SchizophreniaBipolar Disorder
Tretinoin(Vesanoid)
Approved
RARA (retinoic acid receptor alpha); degrades the PML-RARA fusion oncoprotein in APLSmall molecule
Acute Myeloid Leukemia
Verteporfin(Visudyne)
Approved
Benzoporphyrin-derivative photosensitizer for photodynamic therapySmall molecule
Age-Related Macular Degeneration

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

No financial reports recorded.